Crestor vs Praluent: Cost and Access Head-to-Head

How the Two Drugs Work Differently

Rosuvastatin is a high-intensity HMG-CoA reductase inhibitor (statin) that blocks cholesterol synthesis in the liver, upregulating LDL receptor expression so the liver pulls more LDL cholesterol out of the bloodstream. Alirocumab takes a completely different approach. It is a fully human monoclonal antibody that binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that normally degrades LDL receptors on hepatocyte surfaces 1.

That distinction matters for cost. Statins are small-molecule drugs with decades of generic manufacturing history. PCSK9 inhibitors are biologics produced in living cell cultures, a process that keeps production costs high. Rosuvastatin received FDA approval in 2003, and its patent expired in 2016, opening the door to multiple generic manufacturers 2. Alirocumab was approved in 2015 and remains under patent protection with no biosimilar on the U.S. market as of early 2026 3.

The pharmacologic gap between these two agents is not a matter of one being "better." They occupy different rungs on the treatment ladder.

Retail Price and Out-of-Pocket Cost

A 30-day supply of generic rosuvastatin 20 mg costs between $10 and $30 at most U.S. retail pharmacies, and discount programs like GoodRx or Mark Cuban Cost Plus Drugs routinely list it below $10 4. Brand-name Crestor, when dispensed, carries a retail price near $350 per month, but prescribers almost universally write for the generic now. Out-of-pocket cost is rarely a barrier for rosuvastatin. Even uninsured patients can afford it.

Praluent tells a different story. The wholesale acquisition cost (WAC) for alirocumab 75 mg or 150 mg prefilled pen sits at roughly $487 per month, or $5,850 annually 5. In 2018, Sanofi and Regeneron reduced the list price by about 60% from the original launch price, partly in response to payer pushback and competition from evolocumab (Repatha). Even after the reduction, commercially insured patients without copay assistance face monthly costs between $150 and $500 depending on plan design.

Sanofi's MyPraluent copay card can drop out-of-pocket costs to $0 for eligible commercially insured patients. Medicare Part D beneficiaries do not qualify for manufacturer copay cards due to federal anti-kickback rules, and their cost-sharing in the coverage gap phase can exceed $200 per month before reaching catastrophic coverage. The price difference between these two agents is not a rounding error. It is roughly a 20-fold gap.

Insurance Coverage and Prior Authorization

Every commercial insurer and every state Medicaid formulary in the United States covers generic rosuvastatin without prior authorization. It sits on the lowest formulary tier (Tier 1 or Tier 2) across all major pharmacy benefit managers, including CVS Caremark, Express Scripts, and OptumRx 6.

Praluent coverage is far more restrictive. The American College of Cardiology and the American Heart Association (ACC/AHA) position PCSK9 inhibitors as add-on therapy for patients who have not reached LDL targets on maximally tolerated statin therapy, with or without ezetimibe 7. Insurers enforce this positioning through step therapy and prior authorization requirements.

A typical PA workflow for alirocumab looks like this:

1. The patient must have tried and failed (or be documented as intolerant to) at least two high-intensity statins, usually rosuvastatin 20 to 40 mg and atorvastatin 40 to 80 mg.
2. The patient must have tried ezetimibe 10 mg as add-on therapy.
3. A recent fasting LDL result must show the patient remains above goal (often above 70 mg/dL for ASCVD patients or above 100 mg/dL for primary prevention with familial hypercholesterolemia).
4. The prescriber must document the clinical indication: established ASCVD, heterozygous familial hypercholesterolemia (HeFH), or homozygous FH.

Denial rates on initial PCSK9 inhibitor prior authorizations ranged from 50% to 80% in early post-launch years, though approval rates have improved as payers refined their criteria and as real-world evidence accumulated 8. The 2018 ACC Expert Consensus Decision Pathway noted that "administrative burden associated with prior authorization for PCSK9 inhibitors remains a significant barrier to appropriate use" 7.

Cardiovascular Outcomes: What the Trials Show

These two drugs have been tested in large, randomized outcomes trials, but they were studied in different patient populations and should not be compared head-to-head as if a single trial enrolled both arms.

Rosuvastatin in JUPITER. The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) enrolled 17,802 apparently healthy men and women with LDL cholesterol <130 mg/dL and high-sensitivity C-reactive protein (hsCRP) of 2 mg/L or higher. Rosuvastatin 20 mg reduced the primary composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44% compared with placebo (HR 0.56, 95% CI 0.46 to 0.69, P<0.00001) 6. The trial was stopped early at a median follow-up of 1.9 years because of the clear benefit signal.

Alirocumab in ODYSSEY OUTCOMES. The ODYSSEY OUTCOMES trial randomized 18,924 patients who had experienced an acute coronary syndrome (ACS) event 1 to 12 months before enrollment and were already on high-intensity or maximum-tolerated statin therapy. Alirocumab reduced the primary composite MACE endpoint (coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) by 15% (HR 0.85, 95% CI 0.78 to 0.93, P<0.001) over a median 2.8 years of follow-up 5. A prespecified analysis showed that patients with baseline LDL of 100 mg/dL or higher derived the greatest absolute benefit, with a number needed to treat (NNT) of 16 over three years.

Dr. Gregory Schwartz, lead investigator of ODYSSEY OUTCOMES, stated at the American Heart Association Scientific Sessions: "The benefit of alirocumab was most pronounced in patients with the highest baseline LDL cholesterol, supporting a targeted approach to PCSK9 inhibition rather than broad use" 5.

Both drugs reduce cardiovascular events. The critical difference is positioning. Rosuvastatin is proven in primary prevention for a broad population. Alirocumab is proven as an add-on in secondary prevention for patients whose LDL remains elevated despite statin therapy.

LDL Reduction Potency

Rosuvastatin 20 mg lowers LDL cholesterol by approximately 49% to 55% from baseline as monotherapy 9. The maximum approved dose, 40 mg, pushes LDL reductions slightly higher but carries increased risk of myopathy and proteinuria, so 20 mg is the dose used in most clinical settings.

Alirocumab 150 mg every two weeks, when added on top of statin therapy, reduces LDL by an additional 50% to 62% beyond whatever reduction the statin has already achieved 10. In absolute terms, patients on maximally tolerated rosuvastatin with a residual LDL of 100 mg/dL could expect alirocumab to drop that figure to roughly 40 to 50 mg/dL.

That degree of LDL lowering matters for specific populations. The 2018 ACC/AHA cholesterol guideline states: "For patients with clinical ASCVD who are judged to be at very high risk, it is reasonable to add a PCSK9 inhibitor if LDL-C remains ≥70 mg/dL on maximally tolerated statin and ezetimibe therapy" 7. This threshold defines the clinical scenario where alirocumab's additional potency justifies its cost.

For patients who reach their LDL goal on rosuvastatin alone, there is no evidence that adding alirocumab produces incremental cardiovascular benefit 11.

Side Effect Profiles Compared

Rosuvastatin's most common adverse effects include myalgia (muscle pain) in 2% to 11% of patients, headache, nausea, and elevations in hepatic transaminases. Rhabdomyolysis is rare but reported, particularly at the 40 mg dose and in patients with renal impairment or concomitant use of certain interacting drugs 9. New-onset diabetes occurs at a rate of approximately 2.4 additional cases per 1,000 patient-years on rosuvastatin compared with placebo, as demonstrated in JUPITER 6.

Alirocumab's side effect profile is different. The most frequent adverse events are injection-site reactions (7.2% vs. 5.1% with placebo in pooled ODYSSEY data), nasopharyngitis, influenza, and upper respiratory infections 10. Alirocumab does not cause myalgia or rhabdomyolysis. It does not raise blood glucose or increase diabetes risk. For statin-intolerant patients, this distinction is clinically significant.

Neurocognitive effects were a concern raised during the FDA advisory committee review. The EBBINGHAUS substudy of the FOURIER trial (evaluating evolocumab, a related PCSK9 inhibitor) found no difference in cognitive function between PCSK9 inhibitor and placebo arms over a median of 19 months 12. The FDA label for alirocumab includes a note about neurocognitive adverse event reports but does not include a formal warning.

Who Should Use Which Drug

The decision tree between rosuvastatin and alirocumab is straightforward for most patients.

Start with rosuvastatin if the patient has elevated LDL cholesterol and no prior statin trial, regardless of whether the goal is primary or secondary prevention. Rosuvastatin 10 to 20 mg is first-line for most adults with an estimated 10-year ASCVD risk above 7.5%, per 2018 ACC/AHA guidelines 7.

Consider alirocumab if the patient meets all three conditions: (1) established ASCVD or heterozygous FH, (2) already on maximally tolerated statin plus ezetimibe, and (3) LDL remains at or above 70 mg/dL 7.

Consider alirocumab as near-monotherapy if the patient has documented intolerance to at least two statins (confirmed by rechallenge or clinical assessment) and meets LDL criteria for treatment intensification. In ODYSSEY ALTERNATIVE, alirocumab reduced LDL by 45% in statin-intolerant patients 13.

A patient who tolerates rosuvastatin 20 mg and reaches an LDL of 55 mg/dL does not need alirocumab. The drug's cost and injection burden are not warranted when goal LDL is already achieved.

Practical Access: Pharmacy Availability and Delivery

Generic rosuvastatin is stocked at every retail pharmacy chain in the United States (CVS, Walgreens, Walmart, Rite Aid), every independent pharmacy, and every mail-order pharmacy. No specialty pharmacy handling is required. The drug ships and stores at room temperature.

Praluent requires cold-chain storage (2°C to 8°C) and is dispensed primarily through specialty pharmacies. Patients receive autoinjector pens by mail in insulated packaging. Common specialty pharmacy distributors for Praluent include Accredo (Express Scripts), CVS Specialty, and AllianceRx Walgreens. Patients cannot pick up Praluent at a typical retail pharmacy counter in most markets.

The specialty pharmacy model introduces delays. From the time a prescriber submits an order, the prior authorization process adds 5 to 14 business days. If denied, a peer-to-peer review and appeal can extend the timeline by another 2 to 4 weeks. Rosuvastatin prescriptions are typically filled within 30 minutes of submission.

Switching from Crestor to Praluent

Switching is not a direct substitution. Alirocumab does not replace rosuvastatin. In most cases, alirocumab is added to ongoing statin therapy. The 2018 ACC Expert Consensus Decision Pathway recommends maintaining the statin and adding the PCSK9 inhibitor on top unless the patient is fully statin-intolerant 7.

For truly statin-intolerant patients who are discontinuing rosuvastatin and starting alirocumab, the transition is simple from a pharmacologic standpoint. Stop rosuvastatin. Start alirocumab 75 mg subcutaneously every two weeks. Recheck LDL at 4 to 8 weeks. If LDL remains above target, uptitrate to 150 mg every two weeks 3.

Dr. Jennifer Robinson, a lipidologist at the University of Iowa and co-author of the 2018 ACC/AHA cholesterol guidelines, has noted: "For patients who truly cannot tolerate any statin, PCSK9 inhibitors offer a viable path to meaningful LDL reduction, but the documentation of intolerance must be rigorous before we move to a biologic" 7.

Cost-Effectiveness Data

The Institute for Clinical and Economic Review (ICER) evaluated PCSK9 inhibitors in 2017 and updated its analysis after the 2018 price reductions. At the post-reduction net price of approximately $4,500 to $5,000 per year, ICER estimated the incremental cost-effectiveness ratio (ICER) for alirocumab at $92,000 to $141,000 per quality-adjusted life year (QALY) gained, depending on the population modeled 14. The commonly cited willingness-to-pay threshold in the U.S. is $100,000 to $150,000 per QALY.

For rosuvastatin, generic pricing makes the cost-effectiveness question almost moot. At $10 to $15 per month with a 44% relative risk reduction in primary prevention, rosuvastatin's ICER is well below $10,000 per QALY, making it one of the most cost-effective cardiovascular interventions available 6.

The gap narrows considerably if a future biosimilar to alirocumab enters the market or if the price drops below $2,500 annually, a threshold ICER has identified as the point where PCSK9 inhibitors reach a cost-effectiveness ratio below $50,000 per QALY for high-risk secondary prevention patients.

Medicare and Medicaid Access Considerations

Medicare Part D covers alirocumab, but beneficiaries face the coverage gap (sometimes called the "donut hole"). Under the Inflation Reduction Act of 2022, annual out-of-pocket costs for Part D beneficiaries are capped at $2,000 starting in 2025 15. This cap meaningfully reduces the annual burden for Medicare patients taking Praluent, though $2,000 per year is still 10 to 20 times higher than the annual cost of generic rosuvastatin.

Medicaid covers both drugs, but state Medicaid programs apply their own prior authorization criteria for PCSK9 inhibitors. Some states (e.g., Oregon, New York) have been more permissive with approvals. Others require extensive documentation of statin failure across multiple agents and doses before granting PA.

For dual-eligible patients (those enrolled in both Medicare and Medicaid), cost-sharing is minimal, and access to alirocumab is primarily limited by PA requirements rather than out-of-pocket cost.

Rosuvastatin requires no PA through any state Medicaid program. It is universally accessible across all government payer systems, including the Veterans Affairs formulary and TRICARE.